Strengthening Technology and Product Discovery and Commercialization Capabilities

「• 世界的な半導体需要の拡大に対応すべく、グローバル半導体メーカーへ半導体製造プロセス用高純度溶剤(MMPG、MMPGAC)の生産体制を構築する。 （2029年に事業開始予定）」

「To create new businesses in growth markets, the company established the Business Accelerator Center in April 2025. The center is working to examine business models beyond the conventional framework of research and development and accelerate commercialization through co-creation with internal and external technology seeds, startups and research institutions. PoCs (proofs of concept), joint research, joint patent applications and business scenario studies are progressing across multiple themes, and the company is examining management proposals premised on commercialization from fiscal 2026 onward.」

「2027年度 網干工場 パイロット設備設置」

「Nanodiamonds produced using detonation technology are materials that contribute to achieving carbon negativity by reducing CO2 to CO and enabling its recovery as a resource. The company has established a joint research structure with universities and external research institutions and is moving toward practical implementation in society.」

「The company has also established a joint research structure with universities and external research institutions and is exploring the creation of new materials, processing technologies and production technologies that contribute to carbon neutrality, including nanodiamonds.」

「In April 2023, the company established the Life Science SBU. The Life Science Business Planning Office had previously formulated and advanced business and R&D strategies for the Group’s healthcare-related businesses and prepared for the transition to an SBU. As the direction and business strategy of the business became clear, it was transitioned to the Life Science SBU. The SBU includes the Pharma-Tech BU, which integrates the former CPI Company and Formulation Solutions Business, including a service business focused on India that originated from the chiral column business and the concentration of resources in the genomics and genetics fields, and the Medical Business Development Department, which is working to establish the business foundation for bringing new drug-delivery devices into practical use as a medical-device business. Each initiative will be advanced efficiently.」

「In April 2022, the company established the Biomass Innovation Center and the Inorganic Composite Implementation Research Institute to further accelerate co-creation among industry, academia and government toward achieving the “Four Shifts” for building a circular society set out in its medium-term strategy, “Accelerate 2025-Ⅱ.”」

「In addition, the company established the Inorganic Composite Materials Implementation Research Institute, primarily in the electronic materials field, to advance research on organic-inorganic composite materials and pursue materials development more closely aligned with customer needs.」

「In August 2021, the highly biodegradable cellulose acetate CAFBLO™ (キャフブロ) obtained the international OK biodegradable MARINE certification for marine biodegradability. Applying cellulose chemistry technologies developed over many years, the company identified a molecular structure that biodegrades more readily and developed the new CAFBLO™ product, which maintains the quality of conventional products while further increasing the rate of biodegradation, particularly in marine environments.」

「Under the organizational changes effective 1 April 2021, the company established a Business Creation Center integrating business planning in the Corporate Division with the Research and Development Division, as well as an Evaluation and Analysis Center to develop the evaluation technologies required for business creation. The company will accelerate business creation through a customer-in approach, in which all members engage directly with the market and stay close to customers.」

「The new medical drug-delivery device is based on Pyrotechnic technology. To drive its practical application, development was transferred from the Business Creation Division in January 2021, and development has been strengthened and accelerated with mass production in mind.」

「In December 2020, vaccination began for enrolled subjects, healthy adults, in the “Phase I/II Clinical Trial of a COVID-19 DNA Vaccine” conducted by Osaka University Hospital, a physician-initiated clinical trial, using our new drug-delivery device.」

「In addition, under the organizational changes effective 1 July 2020, engineers involved in production technology were placed under centralized management within the Business Creation Division. Through a structure spanning the Group, we will accelerate the development of new processes and technologies through process innovation and work to build circular processes that coexist with the global environment.」

「We will combine our material development capabilities and production technologies with the cutting-edge technologies of パイクリスタル㈱ to rapidly establish a mass-production system for organic semiconductor devices, including integrated circuits and sensors, and accelerate commercialization.」

「We integrated certain functions of the Production Technology Headquarters with the R&D Headquarters and the New Business Development Office to newly establish the Business Creation Headquarters, accelerating the scaling up, launch and commercialization of new business themes. We also newly established the Research Center directly under the president, with think tank and research functions to link our products and technologies with customer needs.」

「In July 2019, we established a new joint research program, the “Advanced Science and Technology Joint Research Program,” and its laboratory at Kanazawa University, with the aim of creating new products in the cellulose field, our core business.」

「From 29 January 2019, we began offering “Actranza™ Lab,” a jet injector independently developed using our pyrotechnic engineering technology.」

「We will newly install mass-production equipment for silver nanoink at the Arai Plant and begin operations in January 2019.」

「On 30 July 2018, we entered into a comprehensive partnership agreement with Kanazawa University, a national university corporation. We aim to strengthen our relationship, particularly in the field of cellulose research, and increase our contribution to society.」

「We are pursuing the commercialization of functional materials, including functional films, optical materials, pharmaceutical excipients and functional food ingredients, for which market and customer development has progressed.」

「To build a new manufacturing system leading to new business creation, we established the Mechatronics Technology Center and Simulation Technology Center within the Production Technology Division on 1 December 2017 and are working to strengthen core mechatronics and simulation technologies and accelerate their deployment across the Company.」

「From April 2017, we began a joint research course in shock science to elucidate the fundamental principles of shock phenomena occurring during the combustion of high-energy materials and develop technologies for their application.」

「On 1 April 2017, we opened Innovation Park (Himeji, Hyogo Prefecture) as a core site for advancing transformation and innovation across the Daicel Group’s technologies, including research into new products and innovative process technologies and consideration of highly efficient production facilities. We also opened a new building, iCube, within Innovation Park, bringing together technical staff in R&D, production technology, engineering, and environmental and safety functions in the same office and providing a facility for active communication and collaboration not only with related internal departments such as sales, but also with external customers and partner companies.」

「Acquisition of new technologies and products through an open lab, which strengthens collaboration and cooperation with customers, universities and research institutions; development of an open office environment to strengthen interdepartmental collaboration; and introduction of new IT technologies」

「Accordingly, on 1 April 2016, we established the Medical Business Strategy Office within the R&D Headquarters and established the Future Medical Research Center (Suita), linked to the joint research course in high-speed energy therapy with the Graduate School of Medicine at Osaka University.」

「Accordingly, on 1 April 2016, we established the Medical Business Strategy Office within the R&D Headquarters and established the Future Medical Research Center (Suita), linked to the joint research course in high-speed energy therapy with the Graduate School of Medicine at Osaka University.」

「Under a new structure designed to strengthen technology and product discovery and commercialization capabilities, we are steadily pursuing the discovery of new products, development of industrialization processes and consideration of M&A aimed at acquiring new platforms.」